Novavax, Inc. will showcase continued progress on data from its updated COVID-19 vaccine (NVX-CoV2601) and provide an overview of its influenza and COVID-19-Influenza Combination (CIC) vaccine candidates at the World Vaccine Congress 2024 (WVC) in Washington, DC, April 2 to 4, 2024.
| GAITHERSBURG, Md., April 1, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, will showcase continued progress on data from its updated COVID-19 vaccine (NVX-CoV2601) and provide an overview of its influenza and COVID-19-Influenza Combination (CIC) vaccine candidates at the World Vaccine Congress 2024 (WVC) in Washington, DC, April 2 to 4, 2024. New data from Novavax’s ongoing research on its updated XBB.1.5 COVID-19 vaccine in participants who previously received an mRNA vaccine showed robust neutralizing antibody titers for the XBB.1.5 subvariant as well as for the currently circulating JN.1 subvariant. Data also showed that the vaccine’s safety and reactogenicity profile was consistent with its prototype vaccine (NVX-CoV2373). Differences observed in immunoglobulin (IgG) subclass responses and Fcγ-mediated effector functions following mRNA and protein-based COVID-19 vaccinations will be shared. Novavax will also discuss its influenza and CIC vaccine candidates, including a recap of data to date and the timeline for the Phase 3 trial anticipated to start during the second half of 2024. Dr. Robert Walker, Chief Medical Officer, Novavax, will participate in a panel discussion on The Future of COVID-19 Vaccinations on April 3, exploring the benefits of developing broadly protective antigens or combination vaccines. Novavax presentations during WVC:
About Novavax Contacts: Media
SOURCE NOVAVAX, INC | |||||||||||
Company Codes: NASDAQ-NMS:NVAX |
View original content to download multimedia:
